Potential benefits of adaptive intensity‐modulated proton therapy in nasopharyngeal carcinomas
Hideki Minatogawa, Kôichi Yasuda, Yasuhiro Dekura, Seishin Takao, Taeko Matsuura, Takaaki Yoshimura, Ryusuke Suzuki, Isao Yokota, Noriyuki Fujima, Rikiya Onimaru, Shinichi Shimizu, Hidefumi Aoyama, Hiroki Shirato
Abstract
Abstract Purpose To investigate potential advantages of adaptive intensity‐modulated proton beam therapy (A‐IMPT) by comparing it to adaptive intensity‐modulated X‐ray therapy (A‐IMXT) for nasopharyngeal carcinomas (NPC). Methods Ten patients with NPC treated with A‐IMXT (step and shoot approach) and concomitant chemotherapy between 2014 and 2016 were selected. In the actual treatment, 46 Gy in 23 fractions (46Gy/23Fx.) was prescribed using the initial plan and 24Gy/12Fx was prescribed using an adapted plan thereafter. New treatment planning of A‐IMPT was made for the same patients using equivalent dose fractionation schedule and dose constraints. The dose volume statistics based on deformable images and dose accumulation was used in the comparison of A‐IMXT with A‐IMPT. Results The means of the D mean of the right parotid gland ( P < 0.001), right TM joint ( P < 0.001), left TM joint ( P < 0.001), oral cavity ( P < 0.001), supraglottic larynx ( P = 0.001), glottic larynx ( P < 0.001), , middle PCM ( P = 0.0371), interior PCM ( P < 0.001), cricopharyngeal muscle ( P = 0.03643), and thyroid gland ( P = 0.00216), in A‐IMPT are lower than those of A‐IMXT, with statistical significance. The means of, D 0.03cc , and D mean of each sub portion of auditory apparatus and D 30% for Eustachian tube and D 0.5cc for mastoid volume in A‐IMPT are significantly lower than those of A‐IMXT. The mean doses to the oral cavity, supraglottic larynx, and glottic larynx were all reduced by more than 20 Gy (RBE = 1.1). Conclusions An adaptive approach is suggested to enhance the potential benefit of IMPT compared to IMXT to reduce adverse effects for patients with NPC.